Companies /Healthcare

Veeva Systems Inc - Class A

NYSE: VEEV Health Information Services
$285.64
â–² $40.73 (+16.63%) today
Markets open · 4:02pm ET

Q4 2025 Earnings

Reported Mar 5, 2025, 4:05pm ET · SEC source
$1.74
Beat +10.05%
EPS · est. $1.58
$720.9M
Beat +3.07%
Revenue · est. $699.4M
+2.9%
Beating market
VEEV vs S&P since report
7 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
−8%−4%0+4%Mar 5Mar 6report 4:05pm ETearnings−1.7%+1.0%
−8%−4%0+4%Mar 5Mar 6earnings−1.7%+1.0%
VEEV +1.0%S&P 500 −1.7%
−8%−4%0+4%Mar 5Mar 6report 4:05pm ETearnings−2.5%+1.0%
−8%−4%0+4%Mar 5Mar 6earnings−2.5%+1.0%
VEEV +1.0%NASDAQ −2.5%
−8%−4%0+4%Mar 4Mar 13report 4:05pm ETearnings−5.3%−3.5%
−8%−4%0+4%Mar 4Mar 13earnings−5.3%−3.5%
VEEV −3.5%S&P 500 −5.3%
−8%−4%0+4%Mar 4Mar 13report 4:05pm ETearnings−6.5%−3.5%
−8%−4%0+4%Mar 4Mar 13earnings−6.5%−3.5%
VEEV −3.5%NASDAQ −6.5%
+7.37%
Day of report
+4.51%
Next session
−3.53%
One week
−9.06%
30 days

S&P 500 over the same 30 days: −11.93%.

Did VEEV Beat Earnings? Q4 2025 Results

Veeva Systems capped fiscal year 2025 with an outstanding quarter, posting Q4 earnings per share of $1.74 against a consensus estimate of $1.58 — a beat of 10.13% — while revenue of $720.89 million topped the $698.57 million estimate by 3.19% and grew 14.3% year over year. The strongest driver behind the results was an acceleration in subscription services, which reached $608.58 million in the quarter, up 17% year over year, fueled by broad platform adoption across both Commercial and R&D Solutions. Quality Cloud added 41 new customers in the period, while one top 20 biopharma committed to a full Clinical Platform approach in what management described as one of Veeva's largest subscription orders ever. Non-GAAP operating margin expanded sharply to 42.7% from 37.9% a year ago, reflecting meaningful operating leverage. Looking ahead, Veeva guided full fiscal year 2026 revenues of $3.04 billion to $3.06 billion with non-GAAP diluted EPS of approximately $7.32, signaling continued confidence in double-digit growth as its Vault CRM Suite rollout broadens across life sciences.

Key Takeaways
  • Subscription services revenue growth of 17% year over year in Q4
  • Strong execution across both Commercial Solutions and R&D Solutions
  • Operating leverage driving non-GAAP operating margin expansion to 42.7% from 37.9%
  • Deepened strategic partnerships across all customer segments from top 20 biopharmas to emerging biotechs

“It was an outstanding quarter and year of execution and innovation in software, data, and business consulting. These advances set us up for the significant opportunity ahead to help life sciences bring better treatments to more patients, with greater speed and efficiency. I am excited to see what we can accomplish with our customers and the Veeva team in the coming years.”

Veeva Systems CEO, on the earnings call

Forward Guidance & Outlook

For Q1 FY2026 (ending April 30, 2025), Veeva guides total revenues of $726–$729 million, non-GAAP operating income of $307–$309 million, and non-GAAP diluted EPS of $1.74–$1.75. For full fiscal year 2026 (ending January 31, 2026), the company guides total revenues of $3,040–$3,055 million, non-GAAP operating income of approximately $1,300 million, and non-GAAP diluted EPS of approximately $7.32.

VEEV YoY Financials

Q4 2025 vs Q4 2024 · SEC filings Q4 2024 Q4 2025
$0$200.0M$400.0M$600.0M$630.6M$720.9MRevenue$456.7M$539.9MGross Profit$135.3M$188.4MOperating Income$147.4M$195.6MNet Income
$0$200.0M$400.0M$600.0MRevenueGross ProfitOperating IncomeNet Income

VEEV Revenue by Segment

Subscription Services$608.6M+17.0%
Veeva R&D Solutions - Subscription$315.2M
Veeva Commercial Solutions - Subscription$293.4M
Professional Services and Other$112.3M
Veeva R&D Solutions - Professional Services$66.7M
Veeva Commercial Solutions - Professional Services$45.6M

Figures from SEC filings and company reports. Not investment advice.